☆ 4.2 Article

Treatment of Recurrent Low-grade Serous Ovarian Cancer With MEK Inhibitors

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2023)

Related references

Note: Only part of the references are listed.

Review Oncology

New therapeutic opportunities for women with low-grade serous ovarian cancer

Tania Moujaber et al.

Summary: Low-grade serous ovarian cancer (LGSC) is a distinct subtype of ovarian cancer, accounting for about 10% of serous carcinomas. Patients with LGSC typically present at a younger age and have a longer clinical course compared to other subtypes. The primary treatment for LGSC is debulking surgery followed by platinum/taxane chemotherapy. However, the response rates to platinum-based chemotherapy in LGSC are low, leading to the investigation of alternative therapies such as endocrine maintenance therapy and combination targeted therapies.

ENDOCRINE-RELATED CANCER (2022)

Add to Collection

Article Medicine, General & Internal

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial

David M Gershenson et al.

LANCET (2022)

Add to Collection

Article Oncology

MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma

Beryl Manning-Geist et al.

Summary: This study demonstrates that MAPK pathway alterations, including KRAS mutations, are independently associated with platinum sensitivity and prolonged survival in LGSC. However, there is limited genetic data and only a few pathogenic germline mutations were identified in LGSC patients.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression

Dane Cheasley et al.

Summary: This study investigates the genomic profiles associated with estrogen receptor (ER) and progesterone receptor (PR) expression patterns in low-grade serous ovarian carcinoma (LGSOC). The results show that PR-low tumors have a higher fraction of the genome altered by copy number changes compared to PR-high tumors. Higher expression of ER and PR is associated with improved overall survival.

NPJ PRECISION ONCOLOGY (2022)

Add to Collection

Review Oncology

MEK inhibitors for the treatment of non-small cell lung cancer

Jing Han et al.

Summary: BRAF and KRAS mutations play a significant role in NSCLC by activating the RAS/RAF/MEK/ERK signaling pathway. Current approved therapies include BRAF and MEK inhibitors, while combination with other drugs may enhance therapeutic effects. Further research is needed to explore optimal drug combinations for treating lung cancer patients.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Review Oncology

Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review

Caitlin Lazurko et al.

Summary: Low-grade serous ovarian cancer (LGSOC) is a rare form of ovarian cancer with poor response to traditional chemotherapy. Evaluating the efficacy of hormone maintenance therapy (HMT) in LGSOC patients showed significant heterogeneity between studies. Further well-designed trials are needed to confirm the benefit of HMT in this rare subgroup of ovarian cancer.

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Article Oncology

EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer

Rebecca C. Arend et al.

GYNECOLOGIC ONCOLOGY (2020)

Add to Collection

Article Oncology

Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience

Heather J. Dalton et al.

GYNECOLOGIC ONCOLOGY (2017)

Add to Collection

Article Oncology

Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase

Jacek P. Grabowski et al.

GYNECOLOGIC ONCOLOGY (2016)

Add to Collection

Article Oncology

Activity of Bevacizumab in Patients With Low-Grade Serous Ovarian Carcinoma

Peter G. Rose et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2016)

Add to Collection

Article Oncology

Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum

David M. Gershenson et al.

BRITISH JOURNAL OF CANCER (2015)

Add to Collection

Review Oncology

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma

Sarah J. Welsh et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2015)

Add to Collection

Review Oncology

MEK1/2 inhibitors in the treatment of gynecologic malignancies

Caela R. Miller et al.

GYNECOLOGIC ONCOLOGY (2014)

Add to Collection

Article Oncology

Bevacizumab Shows Activity in Patients With Low-Grade Serous Ovarian and Primary Peritoneal Cancer

Rachel N. Grisham et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2014)

Add to Collection

Article Oncology

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

John Farley et al.

LANCET ONCOLOGY (2013)

Add to Collection

Article Oncology

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant

David M. Gershenson et al.

GYNECOLOGIC ONCOLOGY (2009)

Add to Collection

Article Oncology

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum

Kathleen M. Schmeler et al.

GYNECOLOGIC ONCOLOGY (2008)

Add to Collection

Article Obstetrics & Gynecology

Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary

David M. Gershenson et al.

OBSTETRICS AND GYNECOLOGY (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.